The molecular imaging and treatment of neuroendocrine tumors (NETs) with radiolabeled somatostatin analogs represent a milestone in the development of theranostic compounds. Whole-body scintigraphy with 111In-pentetreotide has revolutionized the diagnosis and staging of NETs and the evaluation of treatment outcomes. At present, diagnostic accuracy with positron-emitting radionuclides is greater than 90%. Peptide receptor radionuclide therapy (PRRT) has become a well-accepted treatment for patients with welldifferentiated inoperable or metastatic NETs and disease progression after first-line treatment. Disease control rates (complete or partial remission or stable disease in patients with formerly progressive disease) of up to 95%, with a low incidence of long-term hematologic and renal toxicity, have been reported. In a recently published randomized trial, compared with intensified treatment of midgut NETs with longacting and repeatable octreotide, PRRT reduced the hazard of disease progression and death by 79%. Upcoming developments in PRRT include the use of somatostatin receptor antagonists and a-emitting radionuclides, which may further enhance treatment outcomes.

Additional Metadata
Keywords Neuroendocrine tumors, Peptide receptor radionuclide therapy, Somatostatin receptor, Theranostics
Persistent URL dx.doi.org/10.2967/jnumed.117.191015, hdl.handle.net/1765/101817
Journal The Journal of Nuclear Medicine
Citation
Smit Duijzentkunst, D.A. (Daan A.), Kwekkeboom, D.J, & Bodei, L. (2017). Somatostatin receptor 2-targeting compounds. The Journal of Nuclear Medicine, 58, 54S–60S. doi:10.2967/jnumed.117.191015